# OnCo record paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015" ;
  schema:name "TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer"@en ;
  schema:alternateName "TOPARP-A"@en, "Mateo 2015 olaparib prostate"@en ;
  schema:description "Fifty men whose prostate cancer had exhausted every standard treatment were given a PARP inhibitor and biopsied. A third responded, and almost all the responders were the ones with a broken DNA repair gene, including every man who had lost BRCA2."@en ;
  schema:url <https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa1506859>, <https://pubmed.ncbi.nlm.nih.gov/26510020/>, <https://clinicaltrials.gov/study/NCT01682772> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa1506859> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Mateo J, Carreira S, Sandhu S, et al." ;
  onco:related <https://onco.cc/key-papers/paper-profound-nejm-2020/>, <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:institutions <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/ngs/> ;
  onco:people <https://onco.cc/people/johann-de-bono/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:journals <https://onco.cc/journals/nejm/> .